AZN
The table below shows AstraZeneca PLC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B |
| R&D | $14.23B | $13.58B | $10.94B | $9.76B | $9.74B | $5.99B |
| SG&A | $19.93B |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $19.98B |
| $19.22B |
| $18.42B |
| $15.23B |
| $11.29B |
| Operating income | - | - | - | - | - | - |
| Income tax | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| EPS (diluted) | - | - | - | - | - | - |